BioProcess International East, September 22-25, 2026

Meet Alphalyse at BioProcess International East.

Host cell proteins are receiving more attention than ever: updated ICH guidance and USP best practices, FDA increasingly requesting LC-MS data in submissions, and EMA now “strongly recommending” LC-MS-based HCP characterization early in development.

If you’re developing a protein therapeutic and want to discuss what these evolving expectations mean for your program, come meet Hillary and Scott at BioProcess International East, September 22-25, 2026.

We’re happy to talk about:

• HCP characterization by LC-MS
  Identify and quantify individual HCPs, determine which proteins persist through purification, and flag high-risk impurities that may impact your product quality, stability, or patient safety.
• ELISA-MS™ for stronger HCP control strategies
  Evaluate your ELISA’s reagent coverage, uncover assay blind spots, and receive orthogonal data to support risk assessments, investigations, comparability studies, and regulatory submissions.
• Outsourced LC-MS HCP analysis for CDMOs
  Expand your analytical service offering with expert LC-MS-based HCP analysis without investing in new instrumentation, specialist staff, or in-house method development.

Send us a message below if you’d like to meet us at BPI East.